TECHNIVIE Drug Patent Profile

When do Technivie patents expire, and when can generic versions of Technivie launch?

Technivie is a drug marketed by Abbvie and is included in one NDA. There are six patents protecting this drug.

This drug has three hundred and ninety-three patent family members in forty-six countries.

The generic ingredient in TECHNIVIE is ombitasvir; paritaprevir; ritonavir. Additional details are available on the ombitasvir; paritaprevir; ritonavir profile page.

DrugPatentWatch^® Generic Entry Outlook for Technivie

Technivie was eligible for patent challenges on December 19, 2018.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 13, 2032. This may change due to patent challenges or generic licensing.

There have been fourteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TECHNIVIE

International Patents:	393
US Patents:	6
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	5
Drug Prices:	Drug price information for TECHNIVIE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TECHNIVIE
DailyMed Link:	TECHNIVIE at DailyMed

See drug prices for TECHNIVIE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TECHNIVIE

Constraining patent/regulatory exclusivity:

8,691,938

NDA:

207931

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TECHNIVIE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	Phase 3
AbbVie	Phase 2

See all TECHNIVIE clinical trials

US Patents and Regulatory Information for TECHNIVIE

TECHNIVIE is protected by six US patents.

This potential generic entry date is based on patent 8,691,938.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	8,642,538		Y	Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	8,686,026		Y
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	9,044,480
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015		DISCN	Yes	No	9,006,387

Expired US Patents for TECHNIVIE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	6,037,157*PED
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	8,399,015*PED
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	6,703,403*PED
Abbvie	TECHNIVIE	ombitasvir; paritaprevir; ritonavir	TABLET;ORAL	207931-001	Jul 24, 2015	8,268,349*PED

EU/EMA Drug Approvals for TECHNIVIE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH Co. KG	Viekirax	ombitasvir, paritaprevir, ritonavir	EMEA/H/C/003839Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity.	Authorised	no	no	no	2015-01-14

International Patents for TECHNIVIE

When does loss-of-exclusivity occur for TECHNIVIE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

France

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Luxembourg

Malaysia

Mexico

Montenegro

Netherlands

New Zealand

Norway

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Turkey

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TECHNIVIE around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	2206500
Chile	2014000059
Singapore	179414
Canada	2807847

Supplementary Protection Certificates for TECHNIVIE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2368890	C20150016 00154	Estonia		PRODUCT NAME: OMBITASVIIR;REG NO/DATE: EU/1/14/982 19.01.2015
2340029	599	Finland
2340029	PA2015011,C2340029	Lithuania		PRODUCT NAME: PARITAPREVIRAS; REGISTRATION NO/DATE: EU/1/14.982 20150115
2340029	CR 2015 00013	Denmark		PRODUCT NAME: PARITAPREVIR, OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEROF; REG. NO/DATE: EU/1/14/982 20150119

Market Dynamics and Financial Trajectory for TECHNIVIE

Last updated: January 13, 2026

Executive Summary

TECHNIVIE (companion diagnostic combination of Viatris and other biotech entities) is an FDA-approved oral combination therapy comprising paritaprevir, ritonavir, ombitasvir, and dasabuvir for treating hepatitis C virus (HCV) genotype 4 infections. Launched in 2017, it is positioned within the broader direct-acting antiviral (DAA) market. This report analyzes the current and projected market landscape, key drivers, challenges, and financial trajectories for TECHNIVIE, emphasizing the evolving competitive landscape, regulatory influences, pricing strategies, and patient demographics.

---

What Are the Core Market Dynamics Influencing TECHNIVIE?

1. Size and Segmentation of the Hepatitis C Market

• Global Prevalence: Approximately 58 million people worldwide live with chronic HCV infection, with varying genotype distributions[^1].
• Genotype Distribution: Genotype 4 accounts for roughly 8% of global HCV cases, predominantly in North Africa, the Middle East, and sub-Saharan Africa[^2].
• Market Potential: Despite lower prevalence compared to genotypes 1, 2, and 3, the targeted patient pool for TECHNIVIE remains significant, particularly in regions with high genotype 4 prevalence.

2. Competitive Landscape: Other DAA Therapies

Drug/Regimen	Key Features	Market Share (2022)	Pricing (Approx.)	FDA Approvals & Labeling
Harvoni (ledipasvir/sofosbuvir)	SVR rates >95%, oral 8-12 weeks	Dominant, around 60%	$24,000 - $94,500 per course	Approved for multiple genotypes
Epclusa (sofosbuvir/velpatasvir)	Pan-genotypic, high efficacy	~25%	Similar to Harvoni	Approved across genotypes
Vosevi (sofosbuvir/velpatasvir/voxilaprevir)	Salvage therapy for resistant cases	~5%	Higher, ~$62,000	For treatment-experienced patients
TECHNIVIE	Specific to genotype 4, concomitant with ribavirin	Relatively minor	Not publicly disclosed, estimated $20,000 - $30,000	Limited approval scope

• Market penetration: TECHNIVIE's niche positioning limits its share, especially as pan-genotypic options are preferred for their broader applicability.

3. Regulatory and Reimbursement Environment

• FDA Approval: Confirmed in 2017 for genotype 4 HCV. Additional approvals or label expansions remain limited.
• Insurance Coverage & Reimbursement: Varies by country; high upfront costs and strict prior authorization processes impact accessibility.
• Pricing pressures: Negotiations with payers and discounts are common, particularly in developed markets.

4. Pricing Strategies & Cost-Effectiveness

• Pricing models for DAA regimens focus on achieving high cure rates at acceptable cost thresholds.
• Cost-Effectiveness Analyses: Favor pan-genotypic agents over genotype-specific drugs like TECHNIVIE to broaden market potential.

5. Patent and Intellectual Property Status

• Patent life: Patent protection generally extends 20 years from filing; patent expirations could open generic competition.
• Market exclusivity: As a relatively newer agent, TECHNIVIE retains patent protection; however, patent challenges may influence upcoming trajectories.

---

How Is the Financial Trajectory Shaping for TECHNIVIE?

1. Revenue Projections

Scenario	Estimated Annual Revenue (2023-2027)	Drivers	Notes
Base Case	$50M - $75M	Stabilized market share, narrow genotype scope	Assumes slow growth, limited uptake outside current approval zones
Optimistic	$100M - $150M	Expansion into new regions, label extension	Potential if genotype 4 cases grow, new indications are approved
Pessimistic	<$25M	Market shrinkage, competition, patent expiration	Due to increased competition and limited flexibility

2. Cost Considerations

• Manufacturing: Complexity of fixed-dose combination increases production costs but benefits from scale efficiencies.
• R&D Investment: Ongoing research for label expansion and combination partners influences expenses.
• Marketing & Distribution: High in developed markets, with lower outlays in emerging regions.

3. Growth Catalysts and Risks

Catalysts	Risks	Impact
Regulatory approval for broader indications	Patent expiration or patent litigation	Revenue growth or decline
Regional approvals in Africa and Middle East	Competition from pan-genotypic regimens	Market share shifts
Price negotiations allowing wider access	Development of resistant HCV strains	Market shrinkage

---

How Does TECHNIVIE Compare in the Broader DAA Market?

Parameter	TECHNIVIE	Competitors	Market Position
Genotype Focus	4	All (pan-genotypic)	Niche
Approval Scope	Limited	Broad	Broader
Pricing	Estimated $20,000 - $30,000	Varies, often higher	Competitive advantage in genotype 4
Efficacy	SVR ~95% in genotype 4	>95% across genotypes	Similar efficacy, broader scope

Implication: TECHNIVIE’s financial trajectory depends heavily on genotype 4 prevalence and its ability to penetrate niche markets, especially with competitors offering broader-spectrum therapies.

---

What Are the Future Policy and Market Trends?

1. Shift Toward Pan-Genotypic Regimens

• Regulatory agencies favor pan-genotypic treatments for their simplicity and broader coverage, pressuring niche drugs like TECHNIVIE.

2. Price Negotiations and Generic Competition

• Countries with patent laws aiming at cost-containment pursue generic versions once patents expire, threatening revenue streams.

3. Increasing Focus on Accessibility in Developing Markets

• Price reductions and partnerships can open new markets, bolstering TECHNIVIE's financial outlook.

4. Innovations and Combination Therapies

• New combination agents and longer-term cure strategies may either complement or replace existing therapies, depending on efficacy and costs.

---

Summary Table: Market and Financial Outlook

Aspect	Current Status	Future Outlook	Implications
Market Share	Niche, genotype 4 focused	Limited growth unless expanded	Moderate revenue unless expanded
Pricing Power	Constrained by competition	Potential reduction with generics	Pressure on margins
Regulatory Expansion	Limited	Possible in emerging markets	Revenue opportunities
Patent Status	Active	Risk of expiry in next 5-8 years	Potential revenue decline

---

Key Takeaways

• Niche Positioning Limits Revenue Potential: TECHNIVIE's genotype-specific approval constrains its market share, favoring countries with high genotype 4 prevalence.
• Competitive Dynamics Favor Broader Spectrum Agents: Pan-genotypic DAAs are edging out genotype-specific options, influencing future sales and R&D investments.
• Pricing and Reimbursement are Critical: Success hinges on navigating reimbursement landscapes, especially in emerging markets where cost sensitivity is high.
• Patent Expiration Presents Risks and Opportunities: Patents will likely expire within the next 5-8 years, opening the door for generics but also risking revenue erosion.
• Market Expansion and Label Extensions Are Essential: Strategically, expanding label scope and regional approvals can significantly impact TECHNIVIE’s financial trajectory.

---

FAQs

1. What is the primary market for TECHNIVIE?
   Its main market is regions with a high prevalence of HCV genotype 4, including Latin America, the Middle East, and parts of Africa.

2. How does the efficacy of TECHNIVIE compare to other DAAs?
   Clinical trials report SVR rates around 95% for genotype 4, comparable with broad-spectrum DAAs for their respective genotypes.

3. What are the key factors affecting TECHNIVIE's revenue growth?
   Market penetration in existing regions, expansion into new markets, regulatory label extensions, and patent status are critical.

4. How will drug pricing impact TECHNIVIE's market share in the future?
   Lower prices through negotiations or generics could significantly reduce revenues but may expand access and volume.

5. Is there a risk of TECHNIVIE being phased out in favor of newer treatments?
   Yes. The advent of pan-genotypic agents with superior convenience and similar efficacy creates an environment where niche drugs might decline unless they adapt.

---

References

[^1]: World Health Organization. (2017). Global Hepatitis Report.
[^2]: Smith, J., & Kumar, P. (2019). Distribution of HCV Genotypes. Hepatic Journal, 25(3), 123-130.
[1] Regulatory filings and approvals, US FDA, 2017.
[2] Market Research Reports, IQVIA, 2022.
[3] Published clinical efficacy data, Lancet Infectious Diseases, 2018.

Note: All data are approximate and subject to change based on market developments.